Exscalate Logo

Accelerating the future of drug discovery

At Exscalate we master biological complexity combining our knowledge of pharmacology, artificial intelligence (AI) and supercomputing to design better drugs faster.

Latest News and Updates

Working in partnership with pioneering biopharma start-ups and through collaborations with ambitious European projects, Exscalate’s AI-driven supercomputing platform is accelerating drug discovery with some very promising outcomes.
Finding a cure for dry eye disease
27th July 2022
In partnership with Harvard Medical School spin-off, Aramis Biosciences, Exscalate was used to rapidly identify a lead compound for the previous unmet need of an effective treatment for Dry Eye Disease. The project progressed from zero to Phase II investigational new drug approval in just 14 months.
Identifying new innovative treatments for fibrosis and cancer
24th October 2023
In 2022 Dompé farmaceutici announced a strategic collaboration with and investment in Engitix as part of Engitix s $54m series A financing.
Exscalate4Cov is now a book on High-Performance Computing for COVID Drug Discovery
24th October 2023
Springer's recently published Exscalate4CoV: High-Performance Computing for COVID Drug Discovery opens a window on what can be, and has been done with these new tools right in the middle of the worst pandemic living humans have seen.


We have formed many successful partnerships. Together we are accelerating drug discovery.